RICERCA ITALIANA     

Programmi di ricerca simili:

• 1 - Patogenesi molecolare ed analisi sequenziale di interazioni cellulari e marcatori biologici di progressione di malattia e di resistenza al trattamento nella leucemia linfatica cronica
• 2 - Studio delle basi molecolari e cellulari della risposta alla terapia mirata con inibitori delle tirosin-kinasi per l'ottimizzazione del trattamento delle leucemia Philadelphia positive
• 3 - Alterazioni della cromatina in leucemie
• 4 - Meccanismi di leucemogenesi e terapia target nelle sindromi Mielodisplastiche e nelle Leucemie Acute Mieloidi
• 5 - Nuove frontiere nella stratificazione delle leucemie acute linfoidi (LAL): integrazione tra citogenetica non-convenzionale, genomica e post-genomica
• 6 - Eritropoiesi normale e patologica: caratterizzazione molecolare mediante tecnologie avanzate a resa elevata.
• 7 - Ruolo fisiopatologico di poli(ADPR)polimerasi (PARP) e sue implicazioni terapeutiche.
• 8 - Identificazione, analisi molecolare ed attività funzionale di recettori di membrana e fattori citoplasmatici coinvolti nella crescita e differenziamento di cellule di leucemia linfatica cronica B: impatto sulla prognosi clinica.
• 9 - Marcatori molecolari nel carcinoma del cavo orale e loro impiego nella diagnosi precoce, nella prognosi e nella risposta ai farmaci antiblastici.
• 10 - Caratterizzazione molecolare dell'eritropoiesi:analisi post-genomica e funzionale del profilo di espressione proteica

Classificazione scientifico-disciplinare

• Area scientifico disciplinare: Scienze mediche
  • GENETICA MEDICA
  • ONCOLOGIA MEDICA
  • MEDICINA INTERNA
  • MALATTIE DEL SANGUE

Classificazione brevettuale

• CHEMISTRY; METALLURGY
  • BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

Classificazione geografica

• Regione: Lombardia

Bibliografia

- Alessandrino EP, Amadori S, Cazzola M, Locatelli, Mecucci C, Morra E, Saglio G, Visani G, Myelodysplastic Syndromes: recent advances. Haematologica.2001; 86:1124-57
- C.M. Bender, J.M. Zingg, P.A. Jones, DNA methylation as a target for drug design, Pharm. Res. 15 (1998) 175-187.
- F.Buccisano, F.M.Rossi, A.Venditti, G.Del Poeta, M.C.Cox, E.Abbruzzese, M.Rupolo, M.Berretta, M.Degan, S. Russo, A.Tamburini, L.Maurillo, M.I.Principe, M.Postorino, S.Amadori, V Gattei. CD90/Thy-1 is preferentially expressed on blast cells of high risk acute myeloid leukaemias. Br J Haematol, 125, 203-212, 2004.
-Casorelli I, Offman J, Mele L, Pagano L, Sica S, D'Errico M, Giannini G, Leone G, Bignami M, Karran P. Drug treatment in the development of mismatch repair defective acute leukemia and myelodysplastic syndrome. DNA Repair (Amst) 2003; 2:547-59.
- Catteau A, Morris JR BRCA1 methylation: a significant role in tumour development? Semin Cancer Biol. 2002,12:359-371.
-Crescenzi B,La Starza R,Romoli S,Beacci D,Matteucci C,Barba G,Aventin A,Marynen P,Ciolli S,Nozzoli C,Martelli MF,Mecucci C. Submicroscopic deletions in 5q- associated malignancies. Haematologica.2004,;89:281-5
-Cilloni D, Messa F, Carturan S, Arruga F, Defilippi I, Messa E, Gottardi E,Saglio G. Myelodysplastic syndromes. Ann N Y Acad Sci. 2004 Dec;1028:400-8.
- Cuneo A, Bigoni R, Cavazzini F, Bardi A, Roberti MG, Agostini P, Tammiso E, Ciccone N, Mancini M, Nanni M, De Cuia R, Divona M, La Starza R, Crescenzi B, Testoni N, Rege Cambrin G, Mecucci C, Lo Coco F, Saglio G, Castoldi G .Incidence and significance of cryptic chromosome aberrations detected by fluorescence in situ hybridization in acute myeloid leukemia with normal karyotype. Leukemia 16(9):1745-1751, 2002.
- Di Croce L, Raker VA, Corsaro M, Fazi F, Fanelli M, Faretta M, Fuks F, Lo Coco F, Kouzarides T, Nervi C, Minucci S, Pelicci PG. Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science 2002;295(5557):1079-82.
- van Dijk JP, de Witte T. Monitoring treatment efficiency in MDS at the molecular level; possibilities now and in the future. Leuk Res. 2004 Feb;28(2):101-8.
- Esteller M, Risques RA, Toyota M, Capella G, Moreno V, Peinado MA, Baylin SB, Herman JG. Promoter hypermethylation of the DNA repair gene O(6)-methylguanine-DNA methyltransferase is associated with the presence of G:C to A:T transition mutations in p53 in human colorectal tumorigenesis. Cancer Res 2001, 61: 4689-92.
- Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, Baylin SB, Herman JG.:Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. 2000, 343: 1350-4.
- Esteller M, Gaidano G, Goodman SN, et al . Hypermethylation of the DNA repair gene O(6)-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma.J Natl Cancer Inst. 2002; 94: 26-32.
Falzetti D, La Starza R, Mecucci C. FISH, Micro-FISH and Multicolor FISH to identify rearrangements undetected by classic cytogenetics.Reviews in Clinical and Experimental Hematology. 1998; 7: 3-23.
-Ferrara, F.F., Fazi, F., Bianchini, A.et al. .Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. Cancer Res., 61:2-7, 2001.
- Fosslien E. Molecular pathology of cyclooxygenase-2 in neoplasia Ann Clin Lab Sci. 2000 ; 30: 3-21.
Frohling S, Skelin S, Liebisch C, Scholl C, Schlenk RF, Dohner H, Dohner K, Acute Myeloid Leukemia Study Group, Ulm. Comparison of cytogenetic and molecular cytogenetic detection of chromosome abnormalities in 240 consecutive adult patiens with acute myeloid leukemia. J Clin Oncol. 2002;20:2480-5
-Fuks F, Burgers WA, Brehm A, Hughes-Davies L, Kouzarides T. DNA methyltransferase Dnmt1 associates with histone
deacetylase activity. Nat Genet 2000; 24:88-91.
- Gottlicher, M., Minucci, S., Zhu, P., Kramer, O.H., Schimpf, A., Giavara, S., Sleeman, J.P., Lo Coco, F., Nervi, C., Pelicci, P.G., and Heinzel, T. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J., 24:6969-6978, 2001.
- Gozzini A, Rovida E, Dello Sbarba P, Galimberti S, Santini V. Butyrates as single drug induce histone acetylation and granulocytic maturation: possible selectivity on core binding factor-acute myeloid leukemia blasts. Cancer Res. (in press)
- Greenberg P, Anderson J, de Witte T,et al.. Problematic WHO reclassification of mylodysplastic syndromes. membrers of the International MDS Study Group. J Clin Oncol. 2002;18:3447-52
--Howe RB, Porwit-MacDonald A, Wanat R, Tehranchi R, Hellstrom-Lindberg E. The WHO classification of MDS does make a difference. Blood 2004 May 1; 103(9):3265-70
- Issa JPJ, Garcia-Manero G, Giles FJ, et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2-deoxycytidine (decitabine) in hematopoietic malignancies Blood. 2004;103:1635-1640
- Kuendgen A, Strupp C, Aivado M,et al.. Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid.Blood. 2004 ;104:1266-9
- Jhanwar-Uniyal M. Front Biosci. 2003 Sep 1;8:s1107-17. BRCA1 in cancer, cell cycle and genomic stability.
- Leone G, Mele L, Pulsoni A, Equitani F, Pagano L: The incidence of secondary leukemias. Haematologica 1999, 84, 937-945 .
- Leone G, Voso MT, Sica S, Morosetti R, Pagano L. Therapy related leukemias: susceptibility, prevention and treatment. Leuk Lymphoma. 2001; 41(3-4):255-76.
- G Leone, MT Voso, L Teofili, M Lubbert. Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS . Clinical Immunology 109 (2003) 89-102
-List AF, Vardiman J, Issa JP, Dewitte TM. Myelodysplastic syndromes. Hematology (Am Soc Hematol Educ Program). 2004;297-317
- List A, Kurtin S, Roe DJ, Buresh A, Mahadevan D, Fuchs D, Rimsza L, HeatonR, Knight R, Zeldis JB. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med. 2005 , 10;352:549-57.
- Marks, P., Rifkind, R.A., Richon, V.M., Breslow, R., Miller, T., and Kelly, W.K. Histone deacetylases and cancer: causes and therapies. Nature Rev Cancer., 1:194-202, 2001.
- Martinelli G, Ottaviani E, Buonamici S, Isidori A, Borsaru G, Visani G, Piccaluga Pp, Malagola M, Testoni N, Rondoni M, Nucifora G,Tura S, Baccarani M. Association of 3q21q26 syndrome with different RPN1/EVI1 fusion transcripts Haematologica. 88:1221-1228, 2003.
- Mecucci C. Molecular features of primary MDS with cytogenetic changes. Leuk Res. 1998; 22:293-302.
- Ng MH, To KW, Lo KW, et al.. Frequent death-associated protein kinase promoter hypermethylation in multiple myeloma. Clin Cancer Res 2001, 7, 1724-9.
- Nilsson L, Åstrand-Grundström I, Anderson K, et al. . Involvement and functional impairment of the CD34+CD38-Thy-1+ hematopoietic stem cell pool in myelodysplastic syndromes with trisomy 8. Blood 100,259,2002.
-Nan X, Campoy FJ, Bird A. MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin.
Cell 1997; 88:471-81.
-Parker JE, Mufti GJ, Rasool F, Mijovic A, Devereux S and Pagliuca A. The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to SMD. Blood 96,3932,2000.
- J Pedersen-Bjergaard, MK Andersen, DH Christiansen, and C Nerlov. Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia. Blood 99,1909,2002

Parole Chiave

SINDROMI MIELODISPLASTICHE; ALTERAZIONI CITOGENETICHE; ALTERAZIONI EPIGENETICHE; APOPTOSI; ACETILAZIONE ISTONICA; METILAZIONE DEL DNA; AGENTI DEMETILANTI; MOLECOLE DI ADESIONE; IMMUNOFENOTIPO